Literature DB >> 22245324

Plasmacytoid carcinoma of the bladder: a urothelial carcinoma variant with a predilection for intraperitoneal spread.

Roberto Rafael Ricardo-Gonzalez1, Michael Nguyen, Neriman Gokden, Ankur R Sangoi, Joseph C Presti, Jesse K McKenney.   

Abstract

PURPOSE: Bladder plasmacytoid carcinoma is an invasive urothelial carcinoma subtype that is emphasized for its morphological overlap with plasma cells and metastatic carcinoma. Our experience suggests frequent intraperitoneal spread that is not typical of conventional urothelial carcinoma.
MATERIALS AND METHODS: We identified cases of plasmacytoid urothelial carcinoma diagnosed on radical cystectomy. Patient age, gender, American Joint Committee on Cancer (7th edition) stage, metastatic spread/recurrence sites and clinical disease status at last followup were recorded.
RESULTS: A total of 10 male and 5 female patients 42 to 81 years old were identified. One tumor was pT2, 11 pT3 and 3 pT4. Six of 15 patients (40%) presented with lymph node metastasis and 5 (33%) had intraperitoneal metastasis at cystectomy. These initial sites of metastatic spread included the prerectal space, ovary and vagina, ovary and fallopian tube, bowel serosa, and omentum and bowel serosa in 1 case each. Three patients had subsequent metastasis involving the prerectal space, pleural fluid and small bowel serosa, and bowel serosa in 1 each. Eight patients had followup information available, including 3 who died of disease, 3 with disease and 2 with no evidence of disease.
CONCLUSIONS: Of the patients 33% with the plasmacytoid variant of urothelial carcinoma presented with intraperitoneal disease spread and 20% had subsequent metastasis involving serosal surfaces. The possibility of noncontiguous intraperitoneal spread involving serosal surfaces should be recognized to ensure proper intraoperative staging and clinical followup for patients with plasmacytoid carcinoma.
Copyright © 2012 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22245324     DOI: 10.1016/j.juro.2011.10.145

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  20 in total

1.  SIU-ICUD on bladder cancer: pathology.

Authors:  Eva Compérat; Marek Babjuk; Ferran Algaba; Mahul Amin; Fadi Brimo; David Grignon; Donna Hansel; Ondra Hes; Bernard Malavaud; Victor Reuter; Theo van der Kwast
Journal:  World J Urol       Date:  2018-09-14       Impact factor: 4.226

2.  Perirectal recurrence and intraperitoneal dissemination of urothelial carcinoma as plasmacytoid variant: clinical-imaging-histological findings.

Authors:  Miguel Angel Arrabal-Polo; María Del Carmen Cano-García; Paolo Fabiano; Verónica Martínez-Pagán; Matías Barayobre; Javier González García
Journal:  Int Urol Nephrol       Date:  2015-06-07       Impact factor: 2.370

3.  The Impact of Plasmacytoid Variant Histology on the Survival of Patients with Urothelial Carcinoma of Bladder after Radical Cystectomy.

Authors:  Qiang Li; Melissa Assel; Nicole E Benfante; Eugene J Pietzak; Harry W Herr; Machele Donat; Eugene K Cha; Timothy F Donahue; Bernard H Bochner; Guido Dalbagni
Journal:  Eur Urol Focus       Date:  2017-06-27

4.  [Specific types of bladder cancer].

Authors:  S Bertz; A Hartmann; R Knüchel-Clarke; N T Gaisa
Journal:  Pathologe       Date:  2016-02       Impact factor: 1.011

5.  Bladder Stones Associated with an Aggressive Plasmacytoid Variant of Urothelial Cancer: A Rare Case and Literature Review.

Authors:  Mohammed Alsheikh; Mohammad Faruquz Zaman; Preethi Gopinath; Ahmed Qteishat
Journal:  Curr Urol       Date:  2020-01-07

6.  Plasmacytoid urothelial carcinoma (PUC): Imaging features with histopathological correlation.

Authors:  Andrew D Chung; Nicola Schieda; Trevor A Flood; Ilias Cagiannos; Kien T Mai; Shawn Malone; Christopher Morash; Shaheed W Hakim; Rodney H Breau
Journal:  Can Urol Assoc J       Date:  2017-01-12       Impact factor: 1.862

7.  Plasmacytoid urothelial carcinoma: response to chemotherapy and oncologic outcomes.

Authors:  Leonidas N Diamantopoulos; Ali Raza Khaki; Petros Grivas; John L Gore; George R Schade; Andrew C Hsieh; John K Lee; Todd Yezefski; Evan Y Yu; Michael T Schweizer; Heather H Cheng; Sarah P Psutka; Daniel W Lin; Maria S Tretiakova; Funda Vakar-Lopez; Robert B Montgomery; Jonathan L Wright
Journal:  Bladder Cancer       Date:  2020-03-28

8.  Adenocarcinoma ex-goblet cell carcinoid (appendiceal-type crypt cell adenocarcinoma) is a morphologically distinct entity with highly aggressive behavior and frequent association with peritoneal/intra-abdominal dissemination: an analysis of 77 cases.

Authors:  Michelle D Reid; Olca Basturk; Walid L Shaib; Yue Xue; Serdar Balci; Hye-Jeong Choi; Gizem Akkas; Bahar Memis; Brian S Robinson; Bassel F El-Rayes; Charles A Staley; Christopher A Staley; Joshua H Winer; Maria C Russell; Jessica H Knight; Michael Goodman; Alyssa M Krasinskas; Volkan Adsay
Journal:  Mod Pathol       Date:  2016-06-24       Impact factor: 7.842

Review 9.  Characteristics and clinical significance of histological variants of bladder cancer.

Authors:  Marco Moschini; David D'Andrea; Stephan Korn; Yasin Irmak; Francesco Soria; Eva Compérat; Shahrokh F Shariat
Journal:  Nat Rev Urol       Date:  2017-09-12       Impact factor: 14.432

Review 10.  Variant Histology in Bladder Cancer-Current Understanding of Pathologic Subtypes.

Authors:  Manju Aron
Journal:  Curr Urol Rep       Date:  2019-11-28       Impact factor: 3.092

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.